4.2. union international cancer control prognostic groups. according 2016 tnm classification, following prognostic groups defined: table 2: prognostic groups testicular cancer (uicc, 2016, 8th edn.) stage groupingtnmsstage 0ptisn0m0s0stage ipt1-t4n0m0sxstage iapt1n0m0s0stage ibpt2 - pt4n0m0s0stage isany pt/txn0m0s1-3stage iiany pt/txn1-n3m0sxstage iiaany pt/txn1m0s0any pt/txn1m0s1stage iibany pt/txn2m0s0any pt/txn2m0s1stage iicany pt/txn3m0s0any pt/txn3m0s1stage iiiany pt/txany nm1asxstage iiiaany pt/txany nm1as0any pt/txany nm1as1stage iiibany pt/txn1-n3m0s2any pt/txany nm1as2stage iiicany pt/txn1-n3m0s3any pt/txany nm1as3any pt/txany nm1bany prognostic groups testicular cancerstage ia:primary tumours limited testis epididymis, evidence microscopic vascular lymphatic invasion tumour cells microscopy, sign metastases clinical examination imaging, post-orchidectomy serum tumour marker levels within normal limits. marker decline patients clinical stage (cs i) disease assessed normalisation occurs two consecutive measurements.stage ib:more locally invasive primary tumour, sign metastatic disease.stage is:following orchiectomy tumour markers increase, remain persistently elevated fail decline expected half-lives indicating presence subclinical metastatic disease. presence second gct contralateral testis also excluded. population-based patient series developed countries, 75-80% sgct patients, 55-64% nsgct patients cs disease diagnosis . true cs i, i.e. persistently elevated increasing serum tumour marker levels radical orchidectomy, found approximately 5% nsgct patients .